Ovarian cancer screening and early detection

Women's Health

Volumn 5, Issue 6, 2009, Pages 693-699

  Joyner, Andrea B ^a   Runowicz, Carolyn D ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Biomarkers; CA 125; Ovarian cancer early detection; Ovarian cancer screening; Transvaginal ultrasound

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; COLONY STIMULATING FACTOR 1; KALLIKREIN; LEPTIN; MESOTHELIN; OSTEOPONTIN; PROLACTIN; SOMATOMEDIN B;

AGE DISTRIBUTION; BREAST CANCER; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL TUMOR; DEVELOPED COUNTRY; EARLY DIAGNOSIS; FAMILY HISTORY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; INFERTILITY; MENARCHE; MORTALITY; NULLIPARA; OVARY CANCER; POSTMENOPAUSE; PREVALENCE; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SUBFERTILITY; TRANSVAGINAL ECHOGRAPHY;

AGE FACTORS; BIOLOGICAL MARKERS; CA-125 ANTIGEN; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MASS SCREENING; OVARIAN NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; VAGINA; WOMEN'S HEALTH;

EID: 70549084722     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.09.65     Document Type: Review

References (30)

1. American Cancer Society: Cancer Facts & Figures 2008. Atlanta, GA, American Cancer Society (2008).
2. th Edition), St. Louis, MO, USA, Mosby, 314-319 (2007).
3. Goff BA, Mandel L, Drescher CW et al.: Development of an ovarian cancer symptom index. Cancer 109, 221-227 (2007).
4. Landen CN Jr, Birrer MJ, Sood AK: Early events in the pathogenesis of epithelial ovarian cancer. J. Clin. Oncol. 26, 995-1005 (2008).
5. Shih IeM, KurmanRJ: Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am. J. Pathol. 164, 1511-1518, (2004).
6. Levanon K, Crum C, Drapkin R: New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J. Clin. Oncol. 26, 5284-5293 (2008). • Describes new insights in the pathogenesis of ovarian cancer.
7. Kindelberger DW, Lee Y, Miron A et al.: Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am. J. Surg. Pathol. 31, 161-169 (2007). • Describes new insights in the pathogenesis of ovarian cancer.
8. Dubeau L: The cell of origin of ovarian epithelial tumours. Lancet Oncol. 9, 1191-1197 (2008).
9. Bast RC, Brewer M, Zou C et al.: Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res. 174, 91-100 (2007)
10. U.S. Preventive Services Task Force: Screening for ovarian cancer: recommendation statement. Am. Fam. Physician 71, 759-762 (2005).
11. Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB: CA 125: the past and the future. Int. J. Biol. Markers 13, 179-187 (1998).
12. Moore RG, Bast RC Jr: Biomarkers for ovarian cancer. In: Ovarian Cancer. Bast RC Jr, Markman M (Eds). Remedica, London, UK 35-58 (2009).
13. Menon U, Skates SJ, Lewis S et al.: Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J. Clin. Oncol. 23, 7919-7926 (2005).
14. Menon U, Gentry-Maharaj A, Hallett R et al.: Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 10, 327-340 (2009). •• Prospective study on the use of CA 125 and ultrasound in ovarian cancer.
15. Bast RC Jr, Badgwell D, Lu Z et al.: New tumor markers: CA 125 and beyond. Int. J. Gynecol. Cancer 15(Suppl. 3), 274-281 (2005).
16. th Annual Meeting, Denver, CO, USA 18-22 April 2009.
17. Visintin I, Feng Z, Longton G et al.: Diagnostic markers for early detection of ovarian cancer. Clin. Cancer Res. 14, 1065-1072 (2008).
18. Jurisicova A, Jurisica I, Kislinger T: Advances in ovarian cancer proteomics: the quest for biomarkers and improved therapeutic interventions. Expert Rev. Proteomics 5, 554-560 (2008).
19. Shaaban A, Rezvani M: Ovarian cancer: detection and radiologic staging. Clin. Obstet. Gynecol. 52, 73-93 (2009).
20. van Nagell JR Jr, DePriest PD, Ueland FR et al.: Ovarian cancer screening with annual transvaginal sonography. Cancer 109, 1887-1896 (2007).
21. American College of Obstetricians and Gynecologists Committee Opinion No. 280: The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstet. Gynecol. 100(6), 1413-1416 (2002). (Reaffirmed in 2005).
22. Greene MH, Piedmonte M, Alberts D et al.: A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA 125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. Cancer Epidemiol. Biomarkers Prev. 17, 594-604 (2008).
23. Rebbeck TR, Knauff ND, Domchek SM: Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J. Natl Cancer Inst. 101, 80-87 (2009). •• Reviews surgical interventions in reducing the risk of ovarian cancer in mutation carriers.
24. American College of Obstetricians and Gynecologists Committee on Practice Bulletins: Hereditary breast and ovarian cancer syndrome. Obstet. Gynecol. 113, 957-965 (2009).
25. Eisen A, Lubinski J, Klijn J et al.: Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J. Clin. Oncol. 23, 7491-7496 (2005).
26. Parker WH, Broder MS, Chang E et al.: Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet. Gynecol. 113, 1027-1037 (2009).
27. Buys SS, Partridge E, Greene MH et al.: Ovarian cancer screening in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am. J. Obstet. Gynecol. 193, 1630-1639 (2005).
28. Partridge E, Kreimer AR, Greenlee RT et al.: Results from four rounds of ovarian cancer screening in a randomized trial. Obstet. Gynecol. 113, 775-782 (2009). •• Large randomized study of the initial screening results in the early detection of ovarian cancer for the Prostate, Lung, Colorectal, and Ovarian Cancer study.
29. American Cancer Society. Ovarian cancer. www.cancer.org
30. National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian. NCCN Clinical Practice Guidelines in Oncology V1. Fort Washington, PA, USA (2008). www.nccn.org/professionals/physician-gls/ PDF/genetics-screening